Lung cancer impacts 1 in 17 men and 1 in 18 women.1
NeoGenomics’ lung solution supports the care continuum with profiles that detect genomic alterations relevant to diagnosis, therapy selection, prognosis, and clinical trial options.
We meet you and your patient where they are, whether they are in an early or advanced stage or when there is no tissue.
NEO | Early-stage NSCLC:
- Offers testing for actionable and informative biomarkers in early-stage NSCLC:
- Provides a quick and concise but comprehensive overview of actionable information aligned with the latest in emerging clinical evidence
- Assists in selecting the most appropriate targeted therapies for improved patient outcomes
ALK = anaplastic lymphoma kinase; EGFR = epidermal growth factor receptor; ROS1 = c-ros oncogene 1; PD-L1 = programmed cell death ligand 1.
* (TAT) Turnaround time is 7 days. Results are integrated into a final comprehensive report.
Personalized oncology intervention immediately after an early-stage diagnosis is possible – but it requires the full picture.
NEO | InvisionFirst® - Lung
- Liquid biopsy assay
- Focused panel that detects 37 genes relevant to treatment and management of NSCLC
- 26% more actionable alterations compared to tissue2
- Use at progression for patients progressing on or after chemotherapy or immunotherapy, and for patients progressing on EGFR tyrosine kinase inhibitors (TKIs)
- Timely results delivered within 7 days*
NeoTYPE® DNA & RNA – Lung: Our fast, targeted, tissue-based assay for lung cancers
RNA NGS optimizes gene fusion detection: This profile features RNA-based fusion detection, which has advantages over DNA-based fusion detection with results delivered in 8-10 days.
- RNA detection sensitivity of nearly 100%3 exceeds that of DNA4,5
- Known and novel fusions of targeted genes are reported
- RNA detects expressed rather than predicted fusion sequences, providing better evidence of driver activity6
- RNA avoids technically complex gene intron regions6
Reflex to liquid biopsy is available: If tissue testing doesn’t yield full results, we can proceed with mobile phlebotomy (if requested) and high-sensitivity ctDNA testing with InVisionFirst®-Lung Liquid Biopsy.
NEO | Comprehensive™ - Solid Tumor
- 517 genes by DNA and RNA next-generation
sequencing - Detects key genomic alterations (SNVs, Indels, CNVs, splice variants and fusions) including MSI and TMB
- Inform treatment decisions & identify clinical trials
- Assess patient’s diagnosis and prognosis
- Wide-spectrum screening of genetic markers beyond those found in cancer-specific profiles, in order to identify less frequent markers that cancer-specific profiles could miss
- 8-10 Day Turnaround Time
Find the match for your patient.
Concurrent testing is a practical and time-saving method for identifying actionable biomarkers for therapy decisions, ensuring fully informed choices for the best possible patient outcomes by expediting the time to treatment and reducing delays due to insufficient tissue.
Our test portfolio includes both liquid and solid tumor testing for NSCLC, allowing for simultaneous or reflex testing with NEO | Comprehensive™ - Solid Tumor, a tissue-based test, and NEO | InvisionFirst®-Lung, a blood-based test.
Learn about NGS testing at NeoGenomics
References:
- https://seer.cancer.gov/
- Pritchett, Michael A et al. “Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.” JCO precision oncology vol. 3 PO.18.00299. 25 Apr. 2019, doi:10.1200/PO.18.00299
- NeoGenomics internal data on file.
- Solomon JP, et al. Mod Pathol. 2020;33(1):38-46.
- Benayed R, et al. Clin Cancer Res. 2019;25(15):4712-4722.
- Bruno R, et al. Diagnostics. 2020;10;521.
* Turnaround time for InVisionFirst-Lung is 7 days when samples are sent directly to Research Triangle Park (RTP) for processing.
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients